Therapeutic Conventional Surgery
Therapeutic Conventional Surgery is a medical procedure with 336 clinical trials. Currently 51 active trials ongoing. Historical success rate of 66.9%.
Success Metrics
Based on 160 completed trials
Phase Distribution
Phase Distribution
101
Early Stage
144
Mid Stage
30
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
61.8%
160 of 259 finished
38.2%
99 ended early
51
trials recruiting
336
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery
Clinical Trials (336)
Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases
Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery
Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection
Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer
Drug Details
- Intervention Type
- PROCEDURE
- Total Trials
- 336